List of Excipients in Branded Drug ANECTINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	ANECTINE	succinylcholine chloride	0781-3411	HYDROCHLORIC ACID
Sandoz Inc	ANECTINE	succinylcholine chloride	0781-3411	METHYLPARABEN
Sandoz Inc	ANECTINE	succinylcholine chloride	0781-3411	SODIUM CHLORIDE
Sandoz Inc	ANECTINE	succinylcholine chloride	0781-3411	SODIUM HYDROXIDE
Sandoz Inc	ANECTINE	succinylcholine chloride	0781-9053	HYDROCHLORIC ACID

Anectine Excipient Strategy and Commercial Opportunities for Succinylcholine Injection

Last updated: August 9, 2026

Anectine is the branded formulation of succinylcholine chloride, a short-acting depolarizing neuromuscular blocker used for rapid sequence intubation, skeletal-muscle relaxation during surgery, and mechanical ventilation. Its commercial opportunity is not based on new-molecule exclusivity. It is based on formulation reliability, ready-to-use presentation, preservative-free packaging, supply continuity, and hospital purchasing economics.

The central formulation constraint is chemical instability in aqueous solution. Succinylcholine can hydrolyze to succinic acid and choline, with degradation accelerated by higher temperature and unsuitable pH. A successful product must preserve potency through manufacturing, storage, transport, and emergency use while maintaining compatibility with intravenous administration.

What is Anectine and how is it formulated?

Anectine contains succinylcholine chloride injection at a commonly marketed strength of 20 mg/mL. The product is administered intravenously or intramuscularly and is supplied in sterile injectable presentations for hospital use.[1]

The U.S. prescribing information identifies the formulation as an aqueous solution of succinylcholine chloride in Water for Injection, with pH adjustment using sulfuric acid and/or sodium hydroxide.[1] Product presentations and labeling can vary by manufacturer and market, particularly regarding single-dose versus multiple-dose packaging and the presence of antimicrobial preservatives.

Attribute	Anectine formulation profile
Active ingredient	Succinylcholine chloride
Therapeutic class	Depolarizing neuromuscular blocker
Common strength	20 mg/mL
Route	Intravenous or intramuscular
Dosage form	Sterile aqueous injection
Primary vehicle	Water for Injection
pH control	Acid/base adjustment, commonly sulfuric acid and/or sodium hydroxide
Clinical setting	Operating rooms, emergency departments, intensive-care units
Storage sensitivity	Requires controlled temperature storage and protection from degradation
Commercial status	Mature branded product with generic competition

The excipient burden is deliberately low. Unlike oral products, ophthalmic products, or long-acting injectables, Anectine does not depend on a complex delivery system. The principal technical work is control of pH, degradation, sterility, container closure, and administration convenience.

What excipients are used in Anectine and generic succinylcholine injections?

The core excipient system is Water for Injection plus pH-adjusting agents. Certain presentations may use sodium chloride or antimicrobial preservatives, depending on the manufacturer and whether the vial is single-dose or multidose.

Water for Injection

Water for Injection is the principal vehicle. It must meet compendial requirements for sterility, endotoxins, particulate matter, and conductivity. Because succinylcholine is administered parenterally and may be used during emergency procedures, the vehicle must support rapid withdrawal and dilution without visible precipitation or unacceptable particulate formation.

pH-adjusting agents

The formulation is maintained in an acidic range to improve stability. Sulfuric acid and sodium hydroxide may be used in small quantities to establish the target pH. The pH system is commercially important because changing it can alter degradation rate, injection tolerability, compatibility, and the regulatory comparability package.

Sodium chloride

Some generic succinylcholine products use sodium chloride to create an isotonic or near-isotonic formulation. A sodium-chloride-containing formulation may improve tonicity but can introduce a meaningful formulation difference from the reference product. The difference can affect ANDA sameness, injectable excipient justification, labeling, and clinical bridging requirements.

Preservatives

Multidose presentations may contain antimicrobial preservatives, while single-dose presentations are generally positioned as preservative-free. Preservative selection is a significant commercial and clinical issue. Benzyl alcohol, parabens, and other antimicrobial systems can create restrictions for neonates, pediatric patients, and patients with preservative sensitivities.

For emergency and anesthesia applications, a preservative-free single-dose product has a stronger hospital value proposition even when the active ingredient is identical. The premium is justified by reduced vial manipulation, lower contamination concerns, and suitability for high-acuity patients.

How does succinylcholine stability affect excipient selection?

Succinylcholine is susceptible to hydrolysis in aqueous solution. The formulation strategy must control four variables: pH, temperature, water quality, and container interaction.

pH control

The commercial formulation should maintain a validated acidic pH range that minimizes hydrolysis without creating unacceptable local irritation or compatibility problems. A narrow pH specification is preferable to a broad range because it reduces batch-to-batch variability and supports more predictable shelf life.

A development program should evaluate:

• Hydrolysis rate across the intended pH range
• Formation of succinic acid and choline
• Potency loss under accelerated and long-term conditions
• pH drift during storage
• Compatibility with common infusion fluids
• Effect of terminal sterilization or aseptic processing

A formulation using a conventional buffer may improve pH control but could also alter the reference profile, increase ionic strength, affect degradation, or complicate generic approval. For a mature injectable, minimal excipient architecture is often commercially preferable to a technically elaborate buffer system.

Temperature control

Succinylcholine products require refrigerated storage in many labeled presentations. Temperature excursions are a major operational risk because emergency departments, operating rooms, ambulance services, and automated dispensing cabinets may expose products to room temperature.

A product with validated room-temperature excursion stability could create a meaningful commercial advantage. The value would be highest in:

• Emergency departments
• Ambulance and air-medical systems
• Military and disaster-response procurement
• Operating-room medication carts
• Rural hospitals
• Automated dispensing cabinets

The opportunity depends on generating robust stability data rather than simply adding an excipient. An excipient that improves stability but introduces new toxicity, compatibility, or regulatory concerns may not improve the product’s commercial position.

Chelators and antioxidant systems

A chelator such as disodium edetate could theoretically reduce metal-catalyzed degradation, while an antioxidant system could address oxidative pathways if those pathways are demonstrated. These approaches require caution. They may change the reference formulation, affect injectable safety, create new labeling requirements, or add complexity without solving the primary hydrolysis problem.

For succinylcholine, pH optimization, temperature management, low-permeability packaging, and validated manufacturing controls are likely to offer a better risk-adjusted pathway than an aggressive excipient package.

What formulation patents protect Anectine?

Anectine is based on an old active pharmaceutical ingredient and does not depend on a modern patent estate covering molecular composition, crystal form, targeted delivery, or long-acting release. The principal commercial barriers are regulatory, manufacturing, quality, and supply-chain barriers rather than active patent exclusivity.

The U.S. product was approved decades ago, and generic succinylcholine injections have been marketed through abbreviated applications. FDA’s Orange Book provides the principal reference for listed patents and regulatory exclusivity associated with approved drug products.[2]

IP category	Anectine position
New chemical entity patent	Expired or commercially irrelevant
Composition-of-matter protection	No meaningful current protection expected
Formulation patent	No known blocking estate central to the marketed injection
Method-of-use patent	No meaningful current protection expected for standard anesthesia indications
Orange Book patent barrier	Not the principal generic-entry constraint
Trade-secret value	Manufacturing controls, stability data, fill-finish process, and supplier qualification
Regulatory barrier	Demonstration of sterile injectable quality and product sameness
Commercial barrier	Capacity, shortage resilience, hospital contracts, and controlled distribution

A company should not assume that a new excipient combination creates enforceable market protection. A formulation patent would need to claim a technically defensible composition or performance advantage, such as materially improved room-temperature stability, reduced degradation, or a specific container-closure system. Even then, an ANDA applicant could potentially design around the claims.

When does Anectine lose exclusivity?

Anectine’s traditional small-molecule exclusivity has expired. Generic entry is therefore governed primarily by FDA approval, product availability, manufacturing capacity, and any current regulatory restrictions rather than by a remaining branded patent term.

The expected generic pathway is an ANDA referencing the listed drug, provided the applicant can establish pharmaceutical equivalence and bioequivalence or satisfy the applicable injectable-product requirements. For a simple aqueous injectable solution, the regulatory focus typically includes:

• Same active ingredient
• Same strength
• Same dosage form
• Same route of administration
• Pharmaceutical equivalence
• Sterility and endotoxin control
• Particulate matter control
• Container-closure integrity
• Stability and impurity control
• Appropriate labeling

Are Paragraph IV challenges relevant to Anectine?

Paragraph IV litigation is unlikely to be the principal issue for a mature succinylcholine injection without meaningful unexpired Orange Book patent listings. If a listed patent exists for a particular presentation or formulation, an ANDA applicant could use a Paragraph IV certification to challenge it. The commercial significance would depend on whether the patent covers the reference product broadly or only a narrow presentation.

The more realistic risk for Anectine is not a blockbuster patent challenge. It is substitution by generic manufacturers with lower acquisition prices, improved availability, or packaging better suited to hospital workflow.

What excipient strategy offers the strongest commercial opportunity?

The highest-value strategy is a differentiated injectable platform that preserves the simplicity of the reference product while solving operational problems.

1. Preservative-free single-dose vial

A preservative-free single-dose vial is the lowest-risk differentiation strategy. It can target operating rooms, emergency departments, pediatric hospitals, and institutions seeking to reduce multidose vial handling.

Commercial advantages include:

• Lower contamination concern
• Easier compliance with medication-use policies
• Better positioning for pediatric and neonatal environments
• Simplified pharmacy stocking
• Lower risk of preservative-related restrictions
• Compatibility with barcode medication administration

The principal limitation is higher packaging cost per dose and more waste if demand is unpredictable.

2. Ready-to-use prefilled syringe

A prefilled syringe could reduce preparation time during rapid sequence intubation and limit vial-to-syringe transfer. The presentation would need to address:

• Syringe material compatibility
• Extractables and leachables
• Plunger integrity
• Silicone-oil interaction
• Needle-free connector compatibility
• Long-term stability
• Human-factors validation
• Label readability during emergency use

A prefilled syringe could command a higher price than a vial if hospitals value reduced preparation steps and lower medication-error risk. The market is likely narrower than the standard vial market because anesthesia departments may prefer existing syringe preparation practices.

3. Room-temperature-stable presentation

A product with validated room-temperature stability could create the strongest logistical differentiation. This would reduce cold-chain dependence and support stocking in emergency carts and mobile care settings.

The product would need a clear label and excursion protocol. Stability claims must distinguish between controlled room-temperature storage, temporary temperature excursions, and prolonged exposure to heat. A claim of room-temperature stability would also require close evaluation of degradation impurities and container-closure performance.

4. Low-dead-volume and waste-reduction packaging

A low-dead-volume syringe or vial could reduce residual product waste. This matters in high-volume operating rooms and hospital systems that track medication cost at the dose level.

The opportunity is incremental rather than transformative. Packaging savings must exceed the costs of new tooling, validation, device compatibility, and regulatory change.

5. Standardized concentration strategy

The 20 mg/mL concentration is familiar to clinicians. A lower or higher concentration could create dosing or error risks and would require stronger clinical justification. The commercial preference should be to maintain the established concentration while improving packaging and workflow.

What manufacturing and IP barriers affect commercial entry?

The active ingredient is not difficult to identify, but sterile injectable manufacturing is demanding. The key barriers are operational.

Sterile manufacturing

Manufacturers need validated aseptic processing or a suitable terminal sterilization process, depending on formulation and container system. The process must control:

• Bioburden
• Endotoxins
• Visible and subvisible particles
• Fill-volume accuracy
• Container-closure integrity
• Degradation impurities
• Batch sterility assurance

API supply

Succinylcholine chloride is a mature API, but the number of qualified suppliers may be limited relative to common oral APIs. Supplier qualification, impurity profiling, change-control management, and continuity planning can affect gross margin and product availability.

Container closure

Glass vials remain commercially practical, but polymer containers and prefilled syringes may improve logistics. Each change introduces extractables and leachables testing, adsorption assessment, permeability analysis, and stability work.

The main defensible know-how may reside in:

• API impurity control
• pH adjustment sequence
• Dissolution and mixing conditions
• Hold-time management
• Sterile filtration parameters
• Fill-finish controls
• Temperature-excursion qualification
• Container-closure selection

These elements may be protected through trade secrets and manufacturing capability rather than patents.

How does Anectine compare with generic succinylcholine products?

Generic succinylcholine products compete primarily on price, supply reliability, presentation, and formulary status.

Commercial factor	Anectine brand	Generic succinylcholine
Clinical active ingredient	Succinylcholine chloride	Succinylcholine chloride
Therapeutic use	Standard hospital indications	Same standard indications
Patent advantage	Limited	Limited barrier to entry
Price position	Usually higher	Usually lower
Formulation differentiation	Reference-product familiarity	May vary by excipient and packaging
Supply value	Brand recognition and supplier relationships	Potentially variable capacity
Hospital switching risk	Low where brand is entrenched	Higher if shortage or price pressure occurs
Upgrade opportunity	New presentations may be harder to justify	Flexible platform for improved packaging

Anectine can retain share through dependable supply and institutional familiarity. A new entrant can compete by offering a lower total cost of ownership rather than merely a lower unit price.

Which companies are challenging or competing with Anectine?

Competition comes from generic injectable manufacturers and hospital-supply providers rather than from biosimilar developers. Succinylcholine is a small molecule, so biosimilar risk does not apply.

The competitive field may include companies with injectable portfolios, contract manufacturing organizations, and firms supplying anesthesia products to group purchasing organizations. The most important competitive variables are:

• FDA approval status
• Current shortage status
• Manufacturing-site reliability
• Number of vial sizes
• Preservative-free availability
• Contract pricing
• Distribution reach
• Product-recall history
• Ability to maintain supply during demand spikes

A current company-by-company ranking requires live FDA and procurement data. The commercial assessment should rely on active National Drug Code records, Drugs@FDA approvals, current shortage listings, and hospital contract data rather than historical brand ownership alone.[2-4]

What FDA regulatory pathway applies to an improved Anectine formulation?

A conventional generic formulation would normally pursue an ANDA if it meets the relevant sameness requirements. A materially different formulation, presentation, or stability profile could require a 505(b)(2) application, depending on the proposed differences and FDA’s determination.

ANDA pathway

An ANDA is most suitable for:

• Same strength
• Same dosage form
• Same route
• Same active ingredient
• Comparable inactive-ingredient profile
• Standard vial presentation
• No material new clinical claims

The applicant must justify any inactive-ingredient differences for a parenteral product. FDA’s Inactive Ingredient Database can support excipient precedent analysis, but precedent does not eliminate the need for product-specific safety and quality justification.[5]

505(b)(2) pathway

A 505(b)(2) strategy may be relevant for:

• A new prefilled syringe
• A substantially different excipient system
• New storage claims
• A novel container
• A new dosage strength
• A clinically meaningful administration advantage

The pathway can support differentiated commercial positioning, but development cost and approval risk are higher than for a conventional ANDA.

What revenue exposure and market opportunities exist?

Succinylcholine is a hospital injectable with recurring demand but limited unit-price expansion. Revenue exposure is concentrated in emergency airway management, surgery, and critical care.

The most attractive commercial segments are:

1. Large hospital systems with centralized purchasing
2. Emergency departments requiring rapid access
3. Pediatric and neonatal institutions seeking preservative-free products
4. Ambulatory surgery centers
5. Military and emergency-response procurement
6. Hospitals affected by injectable neuromuscular-blocker shortages
7. International markets with inconsistent cold-chain infrastructure

A differentiated presentation can improve net pricing, but the addressable market remains constrained by the availability of established generic vials. The strongest investment thesis is usually supply reliability plus workflow differentiation, not premium pricing based on the active ingredient.

Key Takeaways

• Anectine is a mature succinylcholine chloride injection with no meaningful new-molecule exclusivity.
• Its core excipient system is intentionally simple: Water for Injection and pH-adjusting agents, with formulation differences across presentations and manufacturers.
• Succinylcholine hydrolysis makes pH control, temperature management, packaging, and impurity control the central technical issues.
• Preservative-free single-dose vials are the lowest-risk commercial upgrade.
• Prefilled syringes and room-temperature-stable products offer greater differentiation but require broader regulatory and stability programs.
• Generic entry is driven by FDA approval, sterile manufacturing capability, supply continuity, and hospital contracting rather than by Paragraph IV litigation.
• Biosimilar risk does not apply because succinylcholine is a small-molecule drug.
• The strongest defensible assets are likely manufacturing know-how, stability data, packaging validation, and reliable supply.
• A conventional ANDA is appropriate for a reference-like product. A materially differentiated formulation may require a 505(b)(2) pathway.
• Commercial success depends on reducing medication-preparation burden and supply-chain risk while preserving the familiar 20 mg/mL concentration.

FAQs

Can a new excipient create exclusivity for a succinylcholine injection?

A new excipient alone rarely creates durable market exclusivity. Protection would require a valid patent claim directed to a specific composition, stability improvement, container system, or manufacturing result that competitors cannot readily design around.

Is a preservative-free Anectine alternative commercially attractive?

Yes. Preservative-free single-dose packaging can support pediatric, neonatal, emergency, and operating-room use. Its commercial value depends on hospital purchasing preferences and whether the product can maintain competitive acquisition cost.

Would a room-temperature formulation justify a premium price?

Potentially. Room-temperature stability can reduce cold-chain costs and improve emergency-cart availability. The premium must be supported by validated stability, clear labeling, and measurable reductions in handling or inventory loss.

Are there formulation-specific patent risks for prefilled succinylcholine syringes?

The primary risks are likely to involve device and container patents rather than Anectine’s active ingredient. A sponsor must evaluate syringe architecture, plunger systems, connector compatibility, and packaging claims before commercialization.

Can a generic manufacturer change Anectine’s excipients?

A generic manufacturer may use different inactive ingredients when FDA requirements are satisfied. For an injectable product, the differences require specific justification addressing safety, compatibility, quality, and pharmaceutical equivalence.

References

1. Pfizer Inc. (n.d.). Anectine: Succinylcholine chloride injection prescribing information. U.S. Food and Drug Administration labeling archive.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (n.d.). Drug shortages database. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. U.S. Department of Health and Human Services.